Create New Account Purchaser Login
Search Tenders
Search
Advanced Search
You are not logged in.

Request for Proposals - Supply of Intravenous Trastuzumab

Details

Tender Closed
RFx ID : 26286813
Tender Name : Request for Proposals - Supply of Intravenous Trastuzumab
Reference # : A1546983
Open Date : Thursday, 8 September 2022 10:30 AM (Pacific/Auckland UTC+12:00)
Close Date  : Wednesday, 26 October 2022 4:00 PM (Pacific/Auckland UTC+13:00)
Tender Type : Request for Proposals (RFP)
Tender Coverage : Sole Agency  [?]
Categories :
  • 51000000 - Drugs and Pharmaceutical Products
Regions:
  • New Zealand
Exemption Reason : None
Required Pre-qualifications : None
Contact : Pharmac Procurement Team
procurement@pharmac.govt.nz
.
Alternate Physical Delivery Address  :
Alternate Physical Fax Number  :
Overview

REQUEST FOR PROPOSALS – Supply of intravenous trastuzumab for the New Zealand subsidised market.


This request for proposals (RFP) letter incorporates the following schedules:
· Schedule 1 specifies the pharmaceutical for which Pharmac is requesting proposals and sets out the background to the RFP and the types of proposals sought;
· Schedule 2 describes the process that Pharmac expects to follow in relation to the RFP;
· Schedule 3 sets out information about the estimated size of the current subsidised market for the pharmaceutical; and
· Schedule 4 contains the RFP form in which you are to provide details of your proposal.

Pharmac is not willing to consider proposals involving funded or unfunded pharmaceuticals or related products other than intravenous trastuzumab in a response to this RFP.

The other attachments in addition to the RFP letter on this GETS listing are an editable version of the proposal form and Pharmac's standard terms and conditions for supply of pharmaceuticals that would form the basis of the contract for supply.

If you wish to submit a proposal, you must submit it to Pharmac via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 4.00 p.m (NZST) on 19 October 2022.